Compare JSPR & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JSPR | VERU |
|---|---|---|
| Founded | 2018 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7M | 42.2M |
| IPO Year | N/A | 1990 |
| Metric | JSPR | VERU |
|---|---|---|
| Price | $1.55 | $2.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | $18.13 | ★ $22.50 |
| AVG Volume (30 Days) | ★ 975.8K | 144.1K |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $2.10 |
| 52 Week High | $7.19 | $7.40 |
| Indicator | JSPR | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 52.31 |
| Support Level | $1.51 | $2.46 |
| Resistance Level | $1.66 | $2.84 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 45.19 | 56.23 |
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.